Join to access to all OVN content. Join for Free

Results for 'Oncology Field Medical'

Presentation Nails and Fails: 7 Tips to Ace Your Next MSL Presentation
Partner Avatar Bridget Rasmusson
Presentation Nails and Fails: 7 Tips to Ace Your Next MSL Presentation

MSL interview tips, scientific presentation skills, hiring managers expectations, medical science liaison communication, virtual interview preparation

The presentation portion of the MSL interview is truly “make or break,” and more often than not, the most highly weighted category of the entire interview process. Countless Hiring Managers have passed on MSL candidates that do not perform well on their scientific presentation – re…

Oct 12th • 1 min read

Virtual Oncology MSL Team Increases KOL Engagement by 120%
Partner Avatar iNIZIO
Virtual Oncology MSL Team Increases KOL Engagement by 120%

Case Studies, Oncology

Case Study (US) The Challenge Client needed comprehensive, scalable and innovative model.​ Goal: Cost-effectively supplement field based MSL team to provide national coverage.​ Objective: Share newly published guidelines with KOLs and gain key strategic insights. The Approach Highly …

Sep 3rd • 1 min read

A Field Test of Major Value Frameworks in Chemotherapy of Nasopharyngeal Carcinoma-To Know, Then to Measure
OVN Avatar Yuan Zhang, Xu Liu, Ying-Qin Li, Ling-Long Tang, Lei Chen, Jun Ma
A Field Test of Major Value Frameworks in Chemotherapy of Nasopharyngeal Carcinoma-To Know, Then to Measure

value framework, European Society for Medical Oncology, Magnitude of Clinical Benefit Scale, American Society of Clinical Oncology, drug therapy, nasopharyngeal neoplasms

The European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO) have developed frameworks to evaluate cancer treatments, particularly for nasopharyngeal carcinoma. A study compared these frameworks using data from 15 randomized controlled trials of systemic c…

Aug 12th • 10 mins read

Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies
OVN Avatar Shani Paluch-Shimon, Nathan I. Cherny, Elisabeth G.E. de Vries, Urania Dafni, Martine J. Piccart, Nicola Jane Latino, Fatima Cardoso
Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies

early breast cancer, magnitude of clinical benefit scale, ESMO-MCBS

The ESMO-MCBS is a validated value scale for assessing solid tumour anticancer treatments, specifically for therapies with curative intent. This document represents the first large-scale field testing of the ESMO-MCBS in early breast cancer to assess its applicability and identify any sh…

Sep 6th • 20 mins read

MSL Evolution: New Trends and Titles That May Emerge
Partner Avatar Tom Caravela
MSL Evolution: New Trends and Titles That May Emerge

digital marketing strategies, SEO best practices, content marketing tips, social media optimization, keyword research tools

The COVID-19 pandemic has clearly had a profound impact on Field Medical Affairs. Has the Medical Science Liaison role changed forever? What new titles, trends and opportunities might emerge as a result of the new age for Field Medical and the evolution of the Medical Science Liaison? Is virtual en…

Apr 5th • 1 min read

Positioning Yourself to Become an MSL in 2022
Partner Avatar Bridget Rasmusson
Positioning Yourself to Become an MSL in 2022

MSL role, clinical background, academic background, research background, industry, MSL Society, conference, scientific expert, therapeutic expertise, pharma companies

After attending the MSL Society’s 9th annual conference in Vegas Last week, I have taken some time to reflect on inquiries our team received about how to effectively step into the MSL role from a clinical, academic, or research background. Industry is a tough nut to crack, but it is absolutely…

Dec 21st • 10 mins read

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

ESMO, hematological malignancies, Clinical benefit scale, EHA

The ESMO-MCBS v1.1 has not been previously validated for haematological malignancies, but it is being explored to avoid duplication of efforts. A feasibility test was conducted using 80 studies related to various haematological malignancies such as acute and chronic leukaemia, lymphoma, myel…

Jan 20th • 20 mins read

Related Topics

Loading...